Assessing the case, so far, for apabetalone as a new drug candidate being investigated for FSHD.


"I don't know how I'm going to live with myself if I don't stay true to what I believe." We evaluate the recent published work describing apabetalone, a small molecule drug from Resverlogix Corp that has been around for awhile and in clinic for other indications and is now being assessed more seriously as a potential therapeutic for FSHD. Overall, while lacking in some areas, this initial study is generally positive and supports that it is a new candidate worthy of further evaluation.


Send in a voice message:

Podden och tillhörande omslagsbild på den här sidan tillhör Peter L Jones, PhD. Innehållet i podden är skapat av Peter L Jones, PhD och inte av, eller tillsammans med, Poddtoppen.